Specifically, it has been observed that the use of the romidepsin (a class I HDAC inhibitor) leads to a significant increase in CCL5 levels, thereby enhancing the immune response in various cancers, including gynecologic cancers and melanoma (13–40). Here, HDAC9 is linked to melanoma.